XLO

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models  Consistent with Xilio's clinically-validated masking technology, XTX601 was well tolerated in non-human primates with a favorable therapeutic index WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2 (CLDN18.2), at the American Association for Cancer Research (AACR) Annual Meeting, taking place from A

4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. "Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board," said Sara Bonstein, chair of the board of direct

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.48 per share, which is equal to the closing price of the company's common stock on April 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on

4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

S-8 - Xilio Therapeutics, Inc. (0001840233) (Filer)

10-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Plan to present new preclinical data at AACR for potential first-in-class masked T cell engager program targeting CLDN18.2 Extended cash runway through the end of 2027 WALTHAM, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and busin

WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California. Poster presentation details, as follows: Title: Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell EngagerSession Category: ImmunologySession Title: T Cell Engagers 1Session Date and Time: Monday, Apr. 20, 2026, from 9:00 a.m. to 12:0

8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that it will implement a 1-for-14 reverse stock split of the issued shares of the company's common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026. The reverse stock split was approved by the company's stockholders at the company's Special Meeting of Stockholders held on February 23, 2026, with the final ratio subsequently determined by the company's Board of Directors. One of the primary goals of the reverse stock split is to increase the per-

8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET. A live webcast can be accessed under "Events & Presentations" in the Investors & Media section of the Xilio Therapeutics website at ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation. About Xilio Therapeutics Xilio Therapeutics is a clinica

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective March 1, 2026, the company granted non-qualified stock options to purchase 50,050 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.5283 per share, which is equal to the closing price of the company's common stock on February 27, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the

8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

424B5 - Xilio Therapeutics, Inc. (0001840233) (Filer)

SCHEDULE 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten offering of pre-funded warrants to purchase 74,780,300 shares of common stock at a price to investors of $0.5349 per pre-funded warrant (the "pre-funded warrants"). Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. The offering is

424B5 - Xilio Therapeutics, Inc. (0001840233) (Filer)